Session 5: Sequencing Therapies for Multiple Myeloma in the Era of Bispecific Antibodies : Episode 7
Patient Case 2: A 39-Year-Old with Progressive Disease After Initial Response to Teclistamab
Melissa Alsina, MD, presents the case of a 39-year-old patient with multiple myeloma who has disease progression after initially responding to teclistamab.
EP: 1.Patient Case 1: A 68-Year-Old with R/R MM Treated with Teclistamab
EP: 2.Selecting Patients with MM for Teclistamab and Optimal Sequencing
EP: 3.Mechanism of Action of Teclistamab in R/R MM and Data Updates
EP: 4.Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM
EP: 5.Bispecific Antibodies in Development for the Treatment of R/R MM
EP: 6.Treatment with Teclistamab Following Progression on CAR-T in R/R MM
Now Viewing
EP: 7.Patient Case 2: A 39-Year-Old with Progressive Disease After Initial Response to Teclistamab
EP: 8.Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics
EP: 9.The Development of Bispecifics-Based Combination Therapies in MM
EP: 10.Patient Case 3: A 52-Year-Old Treated with a Non-BCMA-Targeting Bispecific
EP: 11.Selecting and Sequencing Non-BCMA-Targeting Bispecifics in MM
EP: 12.Recent Data on Non-BCMA Targeting Bispecifics in R/R MM
EP: 13.Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
